Human CD52 Antibody: Features, Benefits, and Applications Explained

Discover our latest innovative product, the Human CD52 Antibody, brought to you by Alpha Lifetech Incorporation. This high-quality antibody is specifically designed for the accurate detection and analysis of CD52 expression in human tissue samples. CD52 is a cell surface antigen that is highly expressed in certain types of cancer, making it a valuable biomarker for cancer diagnosis and prognosis, Our Human CD52 Antibody offers exceptional sensitivity and specificity, allowing for reliable and reproducible results in various research applications. With its advanced technology and rigorous quality control standards, this antibody provides researchers with a powerful tool for studying the role of CD52 in cancer biology and immunotherapy, At Alpha Lifetech Incorporation, we are committed to providing cutting-edge products that meet the evolving needs of the scientific community. Our Human CD52 Antibody is a testament to our dedication to advancing research and improving the understanding of cancer. Contact us today to learn more about how this innovative antibody can enhance your research endeavors

Hot Selling Product

ALP64511-Recombinant Cynomolgus Monkey TNFRSF17/BCMA Protein, His Tag

ALP64534-Recombinant Cynomolgus Monkey CD33L3/Siglec-15 Protein, His Tag

ALP64543-Recombinant Human CD30/TNFRSF8 Protein, His Tag, Avi Tag

ALP64573-Recombinant Human CD152/CTLA-4 Protein, Fc Tag, Avi Tag

ADT1566-RSV-neutralizing Human Antibody (Am14) Biosimilar-(RSV)-Research Biosimilar Antibody

ADT1742-Human Anti-Her2xHer3 Bispecific Antibody

Discovering Human Cd52 Antibody Now Trending Your Trusted OEM Partner

In the ever-evolving world of biomedical research, staying abreast of the latest developments is crucial. One of the most exciting trends currently making waves is the discovery of the Human CD52 Antibody. This antibody is gaining attention not only for its potential in therapeutic applications but also for its significance in understanding various immunological responses. Alpha Lifetech Inc. stands at the forefront of this trend as your trusted OEM partner. With a team of scientists who possess extensive expertise in membrane protein production, Nanobody discovery, and monoclonal development, we are uniquely positioned to support your research needs. As a leader in the production of high-quality reagents, Alpha Lifetech Inc. has successfully launched nearly 10,000 products, including a wide array of membrane protein reagents, cytokines, and drug target antibodies. Our commitment to quality and innovation ensures that you have reliable tools at your disposal to accelerate your research. The emergence of the Human CD52 Antibody is a testament to our dedication to advancing scientific inquiry, providing you with access to the latest breakthroughs and ensuring that we remain your preferred partner in this dynamic field. Whether you are involved in academic research or pharmaceutical development, Alpha Lifetech Inc. is dedicated to delivering tailored solutions to meet your specific needs. With our comprehensive portfolio and unparalleled technical support, you can trust us to empower your projects. Discover the potential of the Human CD52 Antibody with Alpha Lifetech Inc., and together, let’s drive innovation in the life sciences.

Discovering Human Cd52 Antibody Now Trending Your Trusted OEM Partner

Parameter	Value	Description
Antibody Name	Human Cd52	A monoclonal antibody targeting the Cd52 antigen.
Applications	Research, Therapeutics	Used in research and potential therapeutic applications.
Target Antigen	Cd52	A glycoprotein expressed on the surface of lymphocytes.
Isotype	IgG1	The isotype of the antibody indicating its subclass.
Production Method	Hybridoma	Produced using hybridoma technology for monoclonal antibodies.
Target Species	Human	Specifically targets human Cd52 antigen.
Market Trend	Increasing Demand	Growing applications in immunotherapy and research.

Trends in Human Cd52 Antibody Research Over the Years

The line chart above illustrates the increasing trend in research publications related to the Cd52 antibody over the past six years, highlighting the rising interest and advancements in this area of study. In 2018, the number of research publications was relatively low at 50. However, the interest in this specific antibody has surged significantly, with publications rising to 300 by 2023. This growth could be attributed to several factors including advancements in biomedical research, a deeper understanding of the role of the Cd52 antibody in various diseases, and its potential applications in therapeutic interventions. The upward trajectory suggests that researchers are increasingly focusing on the implications of the Cd52 antibody in immunology and treatment modalities, marking it as a crucial area for future studies and developments. As the trend continues, we can expect further innovations and discoveries that may revolutionize current medical practices and enhance patient care.